content_image/279587.jpg
<img src='content_image/279587.jpg'>

## unfolding 

Puma Biotechnology is focused on the clinical development of its lead product candidate PB272, neratinib (oral) , for the treatment of breast cancer, non-small cell lung cancer and other types of solid tumors with a HER2 mutation. 

Additional information on Puma’s clinical trials is available at www.clinicaltrials.gov. 

Puma’s clinical trial pipeline is summarized in the table above. 

